touchIMMUNOLOGY was delighted to speak with Dr Aurélie Najm (University of Glasgow, Glasgow, UK) about B-cell repertoire changes in patients with rheumatoid arthritis and the recent analysis designed to create a nomogram capable of using B-cell repertoire properties to predict response to methotrexate.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The analysis entitled ‘B Cells Repertoire Repartition Predicts Response to Methotrexate at 6 and 12 Months in Naïve RA: A Machine Learning Driven Approach’ (ABSTRACT NUMBER: 0982) was presented at the ACR Convergence, 5-9 November 2021.
- How does the B cell repertoire change in rheumatoid arthritis according to treatment response? (0:19)
- Could you tell us a little about the machine learning based approach you have developed for predicting response to methotrexate? (1:02)
- What were the aims, design of your study assessing this model? (1:57)
- What were the study findings? (2:50)
- What will be the potential impact of this approach on clinical practice? (4:02)
Disclosures: Dr Aurélie Najm has acted as a consultant for BMS, UCB and Chugai; and as a speaker for UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
Share this Video
Related Videos In Rheumatoid Arthritis
NRAS’s mission and impact on the RA community: Ailsa Bosworth, National Rheumatoid Arthritis Society
We had the pleasure of talking with Ailsa Bosworth, a patient advocate for rheumatoid arthritis (RA), and Founder and National Patient Champion for the National Rheumatoid Arthritis Society (NRAS), UK. In this interview, Ailsa explores NRAS’s profound impact on the RA community, and her role and experiences within the NRAS, and pivotal contributions to pioneering […]
A patient’s perspective – journey to diagnosis of seronegative rheumatoid arthritis: Ailsa Bosworth, National Rheumatoid Arthritis Society
We are joined by Ailsa Bosworth, Founder and National Patient Champion for the National Rheumatoid Arthritis Society (NRAS), UK. Ailsa Bosworth is a patient advocate for rheumatoid arthritis (RA) and joins us in this interview to discuss her personal journal to, and following, diagnosis of seronegative RA and the challenges she has faced along the […]
Peter Taylor, EULAR 2023: Current perspectives on the selectivity and safety of JAK inhibitors to target the pathophysiology of rheumatoid arthritis
Janus kinase inhibitors (JAKis) are an emerging new class of disease-modifying medication for the treatment of rheumatoid arthritis (RA). touchIMMUNOLOGY spoke with our Editor-in-Chief Prof Peter Taylor (University of Oxford, UK) to discuss the latest insights into the use, selectivity and safety of JAK inhibitors, and how they are used to target the pathophysiology of […]